 Arrowhead Pharmaceuticals Inc NASDAQ: ARWR and Horizon Therapeutics plc NASDAQ: HZNP have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pay 40 million upfront for global rights to Arrowhead Pharmaceuticals ARO-XDH, an investigational RNAi therapy. 